模型预测:治疗第7天HCV RNA检测不到者,5周DAA方案或可治愈近期或慢性丙肝
分析预测,治疗第7天或第14天HCV RNA检测不到者,疗程可分别缩短至5周或7周。该模型指导的缩短疗程策略或可提高治疗可及性、降低成本并促进HCV消除。
要点
- 治疗第7天HCV RNA检测不到者,模型预测5周DAA疗程或可治愈。
- 治疗第14天HCV RNA检测不到者,模型预测7周DAA疗程或可治愈。
- 该策略为建模预测,尚需临床研究验证。
核心结论
- 模型预测,近期或慢性HCV感染者若治疗第7天或第14天HCV RNA检测不到,疗程可分别缩短至5周或7周。
研究设计与样本
- 基于约300例近期(病程<12个月)或慢性HCV感染者的HCV-宿主参数构建数学模型数据库。
主要发现
- 分析评估了基于治疗第7天或第14天HCV RNA是否检测不到的反应指导治疗策略。
- 预测近期或慢性感染者若第7天HCV RNA检测不到,疗程可缩短至5周。
- 预测近期或慢性感染者若第14天HCV RNA检测不到,疗程可缩短至7周。
关键数值与推荐
- 反应指导治疗策略以治疗第7天或第14天HCV RNA检测不到为缩短疗程的判定标准。
- 模型预测第7天检测不到者疗程可缩短至5周,第14天检测不到者疗程可缩短至7周。
临床怎么用
- 该模型指导的缩短疗程策略或可提高治疗可及性、促进HCV消除并降低成本。
- 对注射吸毒者等HCV高负担关键人群可能尤其有益。
局限性
- 结论基于数学建模预测,尚需临床研究验证。
- 既往基于早期HCV RNA水平的短疗程临床研究使用任意时间点和病毒载量阈值,治愈率不理想。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying individuals with hepatitis C virus (HCV) infection who could be cured with a shorter duration of direct-acting antivirals (DAA) therapy would support the effort to reach HCV elimination goals. To date, clinical studies of short-duration DAA therapy based on early (eg, days 2 or 7) HCV RNA levels (eg, < 500 IU/mL) have used arbitrary time points and viral load thresholds, and yielded suboptimal cure rates. METHODS: A database of HCV-host parameters was built based on mathematically modeling time to cure in about 300 individuals with recent (duration < 12 months) or chronic infection treated with DAAs. Two hundred thousand parameter combinations of viral-host and treatment parameters were generated, each representing an in silico HCV patient under DAA treatment. RESULTS: We assessed response-guided treatment (RGT) strategies based on whether HCV RNA was undetectable on day 7 or day 14 on treatment. The analysis predicted that treatment duration could be shortened to 5 or 7 weeks for people with recent or chronic infection who have undetectable HCV RNA at day 7 or day 14 of treatment, respectively. CONCLUSIONS: Modeling suggested that most people with recent or chronic HCV treated with DAAs will have undetectable HCV RNA by day 7 or 14 and could have their treatment duration reduced to 5 or 7 weeks. This modeling-independent RGT approach could improve treatment access, facilitate HCV elimination, and reduce cost, particularly in key populations most affected by HCV, such as people who inject drugs.
引用
- Goyal A, Cotler SJ, Matthews GV, et al. Modeling Predicts Direct-Acting Antiviral Therapy for 5-Weeks May Cure Recent or Chronic Hepatitis C Infection Among People With Undetectable Viral RNA by Day 7. J Infect Dis. 2026. PMID: 42103311. doi:10.1093/infdis/jiag260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。